Authors: Di Leo, A Larsimont, D Gancberg, D Jarvinen, T Beauduin, M Vindevoghel, A Michel, J Focan, C Ries, F Gobert, P Closon-Dejardin, MT Dolci, S Rouas, G Paesmans, M Lobelle, JP Isola, J Piccart, MJ

Citation: A. Di Leo et al., HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide, ANN ONCOL, 12(8), 2001, pp. 1081-1089

Authors: Piccart, MJ Di Leo, A Beauduin, M Vindevoghel, A Michel, J Focan, C Tagnon, A Ries, F Gobert, P Finet, C Closon-Dejardin, MT Dufrane, JP Kerger, J Liebens, F Beauvois, S Bartholomeus, S Dolci, S Lobelle, JP Paesmans, M Nogaret, JM

Citation: Mj. Piccart et al., Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, J CL ONCOL, 19(12), 2001, pp. 3103-3110